Search by Drug Name or NDC
NDC 00074-0576-30 Venclexta 100 mg/1 Details
Venclexta 100 mg/1
Venclexta is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is VENETOCLAX.
MedlinePlus Drug Summary
Venetoclax is used alone or in combination with obinutuzumab (Gazyva) or rituximab (Rituxan) to treat certain types of chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) or certain types of small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes). It is also used in combination with either azacitidine (Vidaza), decitabine (Dacogen), or cytarabine as a first treatment for acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) in people 75 years of age or older, or in adults who have medical conditions that prevents them from being treated with other chemotherapy medications. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It works by blocking the action of a certain protein in the body that helps cancer cells survive. This helps to kill cancer cells.
Related Packages: 00074-0576-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Venetoclax
Product Information
| NDC | 00074-0576 |
|---|---|
| Product ID | 0074-0576_843d380a-6566-4045-bc90-1c3b633867ec |
| Associated GPIs | 21470080000360 |
| GCN Sequence Number | 075886 |
| GCN Sequence Number Description | venetoclax TABLET 100 MG ORAL |
| HIC3 | V3X |
| HIC3 Description | ANTINEOPLASTIC-B CELL LYMPHOMA-2(BCL-2) INHIBITORS |
| GCN | 41052 |
| HICL Sequence Number | 043284 |
| HICL Sequence Number Description | VENETOCLAX |
| Brand/Generic | Brand |
| Proprietary Name | Venclexta |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Venetoclax |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | VENETOCLAX |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | BCL-2 Inhibitor [EPC], Increased Cellular Death [PE], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208573 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00074-0576-30 (00074057630)
| NDC Package Code | 0074-0576-30 |
|---|---|
| Billing NDC | 00074057630 |
| Package | 1 BOTTLE in 1 CARTON (0074-0576-30) / 28 TABLET, FILM COATED in 1 BOTTLE |
| Marketing Start Date | 2022-06-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |